February 9, 2021 07:28 AM ESTUpdated 11:10 AM
R&D

Bris­tol My­ers Squibb pulls the cur­tain on PhI­II da­ta to back Op­di­vo in the ad­ju­vant set­ting

Nicole DeFeudis

Editor

In its lat­est at­tempt to out­shine Mer­ck’s Keytru­da, Bris­tol My­ers Squibb says it has Phase III da­ta to back Op­di­vo as an ad­ju­vant treat­ment in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times